Arbutus to Report Second Quarter 2018 Financial Results
July 19 2018 - 08:30AM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
Hepatitis B Virus (HBV) therapeutic solutions company, today
announced that it has scheduled its second quarter financial
results, conference call and webcast for Thursday, August 2, 2018.
The schedule for the press release and conference call/webcast are
as follows:
• |
Q2 2018
Press Release: |
August 2,
2018 at 4:00 p.m. ET |
• |
Q2 2018
Conference Call: |
August 2,
2018 at 4:30 p.m. ET |
• |
Domestic
Dial-In Number: |
866-393-1607 |
• |
International Dial-In Number: |
914-495-8556 |
• |
Conference ID Number: |
6966479 |
A live webcast of the conference call can be
accessed through the Investor section of Arbutus' website at
www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling 1-855-859-2056 or
1-404-537-3406, and reference conference ID 6966479.
About ArbutusArbutus Biopharma
Corporation is a publicly-traded (Nasdaq:ABUS) biopharmaceutical
company dedicated to discovering, developing, and commercializing a
cure for patients suffering from chronic Hepatitis B (HBV)
infection. Arbutus is developing multiple drug candidates, each of
which have the potential to improve upon the standard of care and
contribute to a curative combination regimen. For more information,
visit www.arbutusbio.com.
Contact Information
InvestorsMark MurrayPresident and CEOPhone:
604-419-3200 Email: ir@arbutusbio.com
MediaPam Murphy Investor Relations
ConsultantPhone: 604-419-3200Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2023 to Mar 2024